- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00298038
A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
September 6, 2019 updated by: Bausch Health Americas, Inc.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy
The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
299
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must sign an Informed Consent Form
- In remission from past HE
- Uses appropriate birth control measures
- More than or equal to 18 years of age
- Must have potential to benefit from treatment
- Recent prior HE episodes
- Capable and willing to comply with all study procedures
- Participant has personal support available
- Has a certain Model End Stage Liver Disease (MELD) score
- Recent transjugular intrahepatic portosystemic shunt (TIPS) placement or revision
Exclusion Criteria:
- Significant medical conditions, medical conditions that may impact study participation, or Investigator decision not to include
- Allergies to the study drug or similar drugs
- Laboratory abnormalities
- Recent participation in another clinical trial
- History of non-compliance
- Pregnant or at risk of pregnancy, or is lactating
- Recent alcohol consumption
- Active bacterial or viral Infections
- Bowel issues
- Active malignancy
- On a prohibited medication
- Liver transplant expected in near term
- Lactulose intolerance
- Participant shows presence of intestinal obstruction or has inflammatory bowel disease
- Ongoing or recent GI bleed
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rifaximin
Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
|
Oral
Other Names:
|
Placebo Comparator: Placebo
Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
|
Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time To The First Breakthrough Overt HE Episode
Time Frame: Baseline up to 6 Months (168 days)
|
Time to a breakthrough overt HE episode was the duration (number of days) from time of first dose of study drug to the first breakthrough overt HE episode.
A breakthrough overt HE episode was defined as an increase of Conn score from Grade 0 or 1 to ≥2, or an increase in Conn and asterixis score of 1 grade each for those participants who entered the study with a Conn score of 0. Participants who completed the study and did not experience a breakthrough overt HE episode were censored at the time of their 6-month visit.
Participants who terminated early for reasons other than a breakthrough overt HE episode were contacted at 6 months from randomization to determine if they had experienced a breakthrough overt HE event or other outcome.
Participants without breakthrough overt HE were censored at the time of last contact or death, whichever was earlier.
The number of events of a first breakthrough overt HE episode during the treatment interval is presented.
|
Baseline up to 6 Months (168 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time To First HE-related Hospitalization
Time Frame: Baseline up to 6 months
|
Time to first HE-related hospitalization is defined as the duration (number of days) between the first dose of study drug and the date of first HE-related hospitalization.
Participants who discontinued prior to hospitalization due to HE and prior to completion of the 6-month treatment period were censored at the time of discontinuation.
The number of participants with their first HE-related hospitalization per interval is presented.
The number of events of the first HE-related hospitalization during the treatment interval is presented.
|
Baseline up to 6 months
|
Time To Any Increase From Baseline In Conn Score
Time Frame: Baseline up to 6 months
|
Time to any increase in Conn score (mental state grade) was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in Conn score.
Conn score range: Grade 0 (no behavioral abnormality) to Grade 4 (coma; unable to test mental state).
Participants who discontinued prior to experiencing an increase in Conn score and prior to completion of the 6-month treatment period were censored at the time of discontinuation.
The number of events of the initial occurrence of an increase from baseline in Conn score during the treatment interval is presented.
|
Baseline up to 6 months
|
Time To Any Increase From Baseline In Asterixis Grade
Time Frame: Baseline up to 6 months
|
Time to any increase in asterixis grade was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in asterixis grade.
Asterixis (flapping tremor) was determined with the participant holding both arms and forearms extended with wrists dorsiflexed and fingers open for ≥30 seconds per standard practice.
Asterixis grade range: Grade 0 (no abnormal movement) to Grade 4 (almost continuous flapping motions).
Participants who discontinued prior to experiencing an increase in asterixis grade and prior to completion of the 6-month treatment period were censored at the time of discontinuation.
The number of events of the initial occurrence of an increase from baseline in asterixis grade during the treatment interval is presented.
|
Baseline up to 6 months
|
Mean Change From Baseline In Fatigue Domain Score On The CLDQ At End Of Treatment
Time Frame: Baseline, 6 months (End Of Treatment)
|
The 29-item Chronic Liver Disease Questionnaire (CLDQ) questionnaire consists of the following domains: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, and worry.
Participants ranked their level of fatigue by using a 7-point scale from the worst response (1, high degree of fatigue) to the best response (7, minimal fatigue).
|
Baseline, 6 months (End Of Treatment)
|
Mean Change From Baseline In Venous Ammonia Concentration At End Of Treatment
Time Frame: Baseline, Month 6 (End Of Treatment)
|
Venous blood samples (10 mL) were collected at Baseline/Randomization (Day 0) and Days 28, 84, and 168.
Baseline value was the last available value prior to first dose of study drug, and end of treatment value was the last available post-baseline value during the treatment period.
|
Baseline, Month 6 (End Of Treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol. 2018 Sep 28;11:1756284818800307. doi: 10.1177/1756284818800307. eCollection 2018.
- Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. doi: 10.1111/j.1365-2036.2011.04808.x. Epub 2011 Aug 17.
- Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 19, 2005
Primary Completion (Actual)
August 15, 2008
Study Completion (Actual)
August 15, 2008
Study Registration Dates
First Submitted
February 28, 2006
First Submitted That Met QC Criteria
February 28, 2006
First Posted (Estimate)
March 1, 2006
Study Record Updates
Last Update Posted (Actual)
September 18, 2019
Last Update Submitted That Met QC Criteria
September 6, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RFHE3001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Encephalopathy
-
Jinnah Postgraduate Medical CentreNot yet recruitingHepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4Pakistan
-
Sherief Abd-ElsalamTanta UniversityUnknownEncephalopathy, HepaticEgypt
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterInstituto Grifols, S.A.; McGuire Research InstituteCompletedHepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic EncephalopathyUnited States
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnRefractory Hepatic EncephalopathyIndia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Aga Khan UniversityUnknownEncephalopathy, Hepatic | Hepatocerebral Encephalopathy | Portal-Systemic Encephalopathy | Encephalopathy, HepatocerebralPakistan
-
Ain Shams UniversityCompletedMinimal Hepatic Encephalopathy
-
Mansoura UniversityCompletedMinimal Hepatic EncephalopathyEgypt
-
Shanghai Changzheng HospitalEnrolling by invitationHepatic Encephalopathy | Covert Hepatic EncephalopathyChina
-
Bausch Health Americas, Inc.CompletedOvert Hepatic EncephalopathyUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States